Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Tiotropium in the management of chronic obstructive pulmonary disease

P.J. Rees
European Respiratory Journal 2002 19: 205-206; DOI: 10.1183/09031936.02.00271502
P.J. Rees
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Bronchodilators play an important role in the treatment of chronic obstructive pulmonary disease (COPD) and anticholinergics have a long history as an effective and safe treatment. Two papers in this issue extend the information available on tiotropium, through large studies lasting a year. The study by Vincken et al. 1, on behalf of the Dutch/Belgian tiotropium study group, shows better results with the long-acting anticholinergic tiotropium than with ipratropium in COPD. A number of previous publications have shown that the prolonged bronchodilator action of tiotropium, found in single dose studies, is maintained with continued use 2–4. This publication extends shorter studies from the same group 2 and shows that the benefits in spirometry, symptoms, health status and exacerbations were maintained over 12 months of the study. A multicentre study from Casaburi et al. 5, comparing tiotropium with placebo, also confirms the continued effect over 12 months. In addition, tiotropium, compared with placebo, improved health status on COPD-specific measures such as the St George's Respiratory Questionnaire, and general measures, such as the Short Form (SF)-36 5.

Such larger and longer studies are needed for alternative end points, such as exacerbations. The baseline forced expiratory volume in one second of ∼40% predicted in these groups of patients, puts them in the moderate or severe COPD range of current guidelines 6–9. Despite this level of severity, less than half of the participants in either study had an exacerbation during the year and only ∼10% needed admission to hospital.

In the study by Vincken et al. 1, the change in the baseline spirometry 24 h after the last dose of tiotropium was close to 50% of the maximum change achieved, indicating the suitability of once-daily administration of tiotropium. The availability of a long-acting anticholinergic has been promised for some years and the progress of tiotropium from early patient studies to clinical practice seems to have been slow. Tiotropium has the advantage of a prolonged action and relative selectivity since it dissociates more quickly from muscarinic (M)2 receptors than from M1 or M3 receptors 10. In contrast ipratropium is nonselective, blocking M1, M2 and M3 receptors. Blockade of the prejunctional M2 receptors on cholinergic nerve endings may paradoxically increase acetylcholine release since the receptors are inhibitory autoreceptors.

A significant benefit of inhaled anticholinergics is the low incidence of adverse effects. Although dry mouth is seen more frequently with tiotropium than with ipratropium 1, 3, 5 this is usually mild, often transient and has not caused significant patient withdrawal in most published studies.

Alongside the studies of tiotropium have been the trials of long-acting inhaled β-agonists in COPD. Most of these studies have dealt with salmeterol, which has been shown to produce benefits in terms of bronchodilatation 11, symptoms 12, quality of life 13 and time to first exacerbation 14. In combination with ipratropium, the other long-acting β-agonist, formoterol, has also been shown to be more effective than salbutamol in COPD, as measured by airflow and symptom changes 15.

When COPD is more than mild, symptoms will be persistent and bronchodilator therapy will usually be used on a regular basis 16. In these situations, effective long-acting agents should simplify the administration and it is likely that once- or twice-daily administration will improve compliance. Published studies now show that they are also more effective than the short-acting agents on a range of end points. The current studies suggest that when it becomes generally available, tiotropium is likely to become standard anticholinergic therapy in COPD providing more convenient administration with significant benefits over ipratropium.

With the short-acting agents, there has been a long running debate about the comparative merits of anticholinergic and β-agonist bronchodilators in COPD. The availability of the long-acting agents could re-open this debate. It would be interesting to see comparative studies including assessments of quality of life and exacerbations, not just spirometry, although this would require longer, more expensive studies. The eventual practical solution may well be the combination of two long-acting bronchodilators in a condition where reversibility is limited and small changes are worth pursuing. Retrospective analysis of the data from studies of short-acting agents has suggested that exacerbations may be less with the combination or ipratropium alone, than with salbutamol alone 17.

Exacerbations are an area of increasing interest in COPD. They are difficult to study because they are infrequent and difficult to define. However, exacerbations are the cause of considerable inconvenience to patients and expense to the healthcare system. They are associated with a high rate of hospital admission and the alternatives of intensive home support or early discharge teams, to reduce inpatient stays, are also expensive. In the study by Vincken et al. 1 exacerbations per patient per year were reduced from 0.96–0.73. The figures on patients having ≥1 exacerbation suggest that nine patients need to be treated with tiotropium rather than ipratropium for 1 yr to keep one patient free of exacerbations over the year. Looking in the same way at the numbers of patients needing to be treated with respect to hospital admissions, 23 patients treated with tiotropium for 1 yr would prevent one hospital admission. The figures are very similar in the study by Casaburi et al. 5, which compares tiotropium with placebo; seven patients treated to keep one patient exacerbation free for 1 yr and 26 to avoid a hospital admission.

A number of treatments have now been shown to reduce exacerbations in COPD: inhaled corticosteroids in the ISOLDE study 18, mucolytics in the recent Cochrane systematic review 19, long-acting β-agonists 13, 20 and tiotropium 1. Whether these small but significant individual effects can be combined remains to be seen.

The crop of current studies suggest that: if the cost is not prohibitive, bronchodilatation in moderate chronic obstructive pulmonary disease could move to once-daily tiotropium, with or without twice-daily salmeterol or formoterol; a short-acting β-agonist would be available on top for symptom relief; there will be patient and health service benefits in addition to physiological changes in spirometry and the current guidelines 6–9 will need to be adapted to incorporate the emerging evidence; and the effects of combining these agents with inhaled steroids, theophyllines and newer agents, such as phosphodiesterase-4 inhibitors 21, will need further investigation.

    • © ERS Journals Ltd

    References

    1. ↵
      Vincken W, van Noord JA, Greefhorst APM, et al. on behalf of the Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1-yr's treatment with tiotropium. Eur Respir J 2002;19:209–216.
      OpenUrlAbstract/FREE Full Text
    2. ↵
      van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000;55:289–294.
      OpenUrlAbstract/FREE Full Text
    3. ↵
      Casaburi R, Briggs DD, Donohue JF, Serby CW, Witek TJ. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD. Chest 2000;118:1294–1302.
      OpenUrlCrossRefPubMedWeb of Science
    4. ↵
      Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilatation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1136–1142.
      OpenUrlPubMedWeb of Science
    5. ↵
      Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217–224.
      OpenUrlAbstract/FREE Full Text
    6. ↵
      Siafakas NM, Vermeire P, Pride NB, et al. ERS Consensus Statement. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1398–1420.
      OpenUrlFREE Full Text
    7. American Thoracic Society Statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 1995;152:S77–S120.
      OpenUrl
    8. British Thoracic Society guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52:Suppl. 5, S1–S28.
      OpenUrlPubMed
    9. ↵
      National Institutes of Health, National Heart, Lung and Blood Institute. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, NHLBI/WHO workshop report. NIH Publication No. 2701A, March, 2001.
    10. ↵
      Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117:Suppl. 2, 63S–66S.
      OpenUrlCrossRefPubMed
    11. ↵
      van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000;15:878–885.
      OpenUrlAbstract
    12. ↵
      Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnoea and improves lung function in patients with COPD. Chest 1997;112:336–340.
      OpenUrlCrossRefPubMedWeb of Science
    13. ↵
      Jones PW, Bush TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283–1289.
      OpenUrlCrossRefPubMedWeb of Science
    14. ↵
      Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957–965.
      OpenUrlCrossRefPubMedWeb of Science
    15. ↵
      D'Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001;119:1347–1356.
      OpenUrlCrossRefPubMedWeb of Science
    16. ↵
      Rees PJ. Bronchodilators in the therapy of chronic obstructive pulmonary disease. Eur Respir Mon 1998;3:135–149.
      OpenUrl
    17. ↵
      Friedman M, Serby CW, Menjoge SS, Wilson JD, Hilleman DE, Witek TJ Jr. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999;115:635–641.
      OpenUrlCrossRefPubMedWeb of Science
    18. ↵
      Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double-blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297–1303.
      OpenUrlAbstract/FREE Full Text
    19. ↵
      Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001;322:1271–1274.
      OpenUrlAbstract/FREE Full Text
    20. ↵
      ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001;119:1628–1630.
      OpenUrlCrossRefPubMedWeb of Science
    21. ↵
      Compton CH, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a dose-ranging study. Lancet 2001;358:265–270.
      OpenUrlCrossRefPubMedWeb of Science
    PreviousNext
    Back to top
    View this article with LENS
    Vol 19 Issue 2 Table of Contents
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Tiotropium in the management of chronic obstructive pulmonary disease
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Tiotropium in the management of chronic obstructive pulmonary disease
    P.J. Rees
    European Respiratory Journal Feb 2002, 19 (2) 205-206; DOI: 10.1183/09031936.02.00271502

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Tiotropium in the management of chronic obstructive pulmonary disease
    P.J. Rees
    European Respiratory Journal Feb 2002, 19 (2) 205-206; DOI: 10.1183/09031936.02.00271502
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • A step forward for an intermediate cystic fibrosis population
    • Predicting pulmonary hypertension using echocardiography
    • We need to understand why viral infections lead to acute asthma
    Show more Editorials

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2022 by the European Respiratory Society